Drug intelligence / Profile preview

cervus and cucumis polypeptide + leflunomide + methotrexate

Development stage: Preclinical
Lead developer: Sanofi
Modality: Peptides, Small Molecules
Administration: Intramuscular, Oral, Subcutaneous

Overview

A combination therapy consisting of cervus and cucumis polypeptide (CCP), leflunomide, and methotrexate. CCP is a traditional Chinese medicine injection derived from deer horn (*Cervus nippon Temminck*) and sweet melon seeds (*Cucumis melo L*) that promotes fracture healing and has anti-inflammatory properties. Leflunomide and methotrexate are disease-modifying anti-rheumatic drugs (DMARDs) that work by suppressing the immune system to reduce inflammation. This combination may be used to treat rheumatoid arthritis and potentially promote bone healing.

Other names: CCP + LEF + MTX

Targets

DHFR (Dihydrofolate reductase)DHODH (Dihydroorotate dehydrogenase (quinone), mitochondrial)

Beyond the preview

Go deeper on cervus and cucumis polypeptide + leflunomide + methotrexate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on cervus and cucumis polypeptide + leflunomide + methotrexate.

Explore the full profile